Viridian Therapeutics, Inc.\DE (VRDN) Income from Continuing Operations (2013 - 2026)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Income from Continuing Operations came in at 111759000.0 in Q1 2026, down 18.69% year-on-year from 137446798.05 in Q1 2025, and down 12.88% quarter-over-quarter from 99005000.0 in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 111759000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 18.69% year-over-year to 111759000.0 in Q1 2026; TTM through Mar 2026 was 357482000.0, a 5.86% decrease from a year earlier, with the FY2025 full-year figure at 652819000.0, down 37.16% from the prior year.
- Income from Continuing Operations eased to 111759000.0 in Q1 2026 per VRDN's latest filing, from 99005000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 25693000.0 in Q1 2022 and bottomed at 111759000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 68186000.0 (2023), against an average of 66925000.0.
- Across the five-year window, Income from Continuing Operations plunged 165.39% in 2023 and surged 61.69% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 45592000.0 in 2022, then slumped by 84.64% to 84179000.0 in 2023, then climbed by 6.04% to 79092000.0 in 2024, then retreated by 25.18% to 99005000.0 in 2025, then retreated by 12.88% to 111759000.0 in 2026.
- Per Business Quant, the three latest VRDN Income from Continuing Operations figures stand at 111759000.0 (Q1 2026), 99005000.0 (Q4 2025), and 35052000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 229.55 Mn | 229.55 Mn | - | -111.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -111.76 Mn |
| Dec 31, 2025 | -99.01 Mn |
| Sep 30, 2025 | -35.05 Mn |
| Jun 30, 2025 | -111.67 Mn |
| Mar 31, 2025 | -94.16 Mn |
| Dec 31, 2024 | -79.09 Mn |
| Sep 30, 2024 | -91.49 Mn |
| Jun 30, 2024 | -72.96 Mn |
| Mar 31, 2024 | -57.69 Mn |
| Dec 31, 2023 | -84.18 Mn |
| Sep 30, 2023 | -47.66 Mn |
| Jun 30, 2023 | -55.06 Mn |
| Mar 31, 2023 | -68.19 Mn |
| Dec 31, 2022 | -45.59 Mn |
| Sep 30, 2022 | -28.94 Mn |
| Jun 30, 2022 | -29.54 Mn |
| Mar 31, 2022 | -25.69 Mn |
| Dec 31, 2021 | -29.14 Mn |
| Sep 30, 2021 | -14.04 Mn |
| Jun 30, 2021 | -17.96 Mn |